why choose us

First received: May 03, 2023

Clinical Trial: A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Herpes Zoster (HZ)

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Randomized, Double-Blinded, Active-Controlled, 2-Dose Study to Assess the Safety and Immunogenicity of a Herpes Zoster (HZ) Vaccine, JCXH-105, in Healthy Subjects 50 to 69 Years of Age.

Brief Summary: The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster)Participant will be randomized to receive either JCXH-105 or Shingrix.

Read more